Cholesterol lowering meds - pharmacology, PKPD, genomics

5.0(2)
studied byStudied by 40 people
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/116

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

117 Terms

1
New cards

Brand name of atorvastatin

Lipitor

2
New cards

Brand name of fluvastatin

Lescol XL

3
New cards

brand name of lovastatin

Mevacor

4
New cards

brand name of pitavastatin

Livalo

5
New cards

brand name of pravastatin

Pravachol

6
New cards

brand name of rosuvastatin

Crestor

7
New cards

brand name of simvastatin

Zocor

8
New cards

Indication for atorvastatin

hyperlipidemia, primary/secondary prevention of atherosclerotic cardiovascular disease, familial hypercholesterolemia

9
New cards

MOA of -statins

HMG-CoA reductase inhibitors competitively inhibit conversion of HMG-CoA to
mevalonate, an early rate-limiting step in cholesterol synthesis. A compensatory increase in LDL receptors, which bind and remove circulating LDL-cholesterol, results. (Blocks the rate limiting step of cholesterol synthesis)

10
New cards

CI for atorvastatin

Breastfeeding, active liver disease

11
New cards

ADRs for atorvastatin

myopathy, diarrhea, rhabdomyolysis, hepatotoxicity

12
New cards

Key PKPD parameters for atorvastatin

Most statins have a short half-life and should be taken at night (when cholesterol is being produced) - not true for Atorvastatin and Rosuvastatin!! Most statins are lipophilic and have a higher risk of muscle pain

13
New cards

Statin DDI’s

Many statins are metabolized by CYP3A4!!

14
New cards

HMG-CoA Reductase inhibitor impact on cholesterol?

decreases cholesterol synthesis

increases expression of LDL receptors

decreases total cholesterol

decreases LDL 18-55%

decreases TG 7-30%

decreases CRP

increases HDL 5-15%

15
New cards

HMG-CoA Reductase inhibitor pleiotrophic effects

improved endothelial function, atherosclerotic plaque stabilization, decreased oxidative stress and inflammation, inhibition of thrombogenic response

16
New cards

High intensity statins?

Atorvastatin 40-80mg, Rosuvastatin 20-40mg

17
New cards

High intensity statin impact on LDL?

> 50% LDL reduction

18
New cards

Moderate intensity statins?

Atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg, Pravastatin 40-80mg, Lovastatin 40mg, Fluvastatin 80mg, Pitavastatin 2-4mg

19
New cards

Moderate intensity statin impact on LDL?

30-49% LDL reduction

20
New cards

Low intensity statins?

Simvastatin 10mg, Pravastatin 10-20mg, Lovastatin 20mg, Fluvastatin 20-40mg, Pitavastatin 1mg

21
New cards

Low intensity statin impact on LDL?

<30% LDL reduction

22
New cards

Atorvastatin metabolism?

CYP3A4 (less than simva and lova)

23
New cards

Atorvastatin lipophilic?

yes

24
New cards

atorvastatin half-life?

20-30 hours

25
New cards

fluvastatin metabolism?

CYP2C9, CYP3A4

26
New cards

fluvastatin lipophilic?

yes

27
New cards

fluvastatin half-life

~3 hours

28
New cards

Lovastatin metabolism?

CYP3A4

29
New cards

Lovastatin lipophilic?

yes

30
New cards

Lovastatin half-life

1.1-1.7 hours

31
New cards

Pitavastatin metabolism?

glucuronidation

32
New cards

Pitavastatin lipophilic?

yes

33
New cards

Pitavastatin half-life?

8-12 hours

34
New cards

pravastatin metabolism

sulfation

35
New cards

pravastatin lipophilic?

no

36
New cards

pravastatin half-life

2-3 hours

37
New cards

rosuvastatin metabolism

CYP2C9, CYP2C19

38
New cards

rosuvastatin lipophilic?

no

39
New cards

rosuvastatin half-life

19 hours

40
New cards

simvastatin metabolism

CYP3A4

41
New cards

simvastatin lipophilic?

yes

42
New cards

simvastatin half-life

2-3 hours

43
New cards

Examples of CYP3A4 inhibitors:

-azoles, amiodarone

44
New cards

Examples of CYP3A4 inducers:

Phenytoin, rifampin

45
New cards

Side effects of statins:

HMGCA: Hepatotoxicity, myopathy, GI side effects (diarrhea), CPK increase (this enzyme increases in rhabdomyolysis), avoid in breastfeeding

46
New cards

Statin monitoring:

  1. Fasting lipid panel (4-12 weeks after initiation or therapy change, thereafter, 3-12 months as clinically indicated)

  2. transaminases (ALT, AST): baseline, may measure in patients with symptoms suggesting hepatotoxicity

  3. Monitor for new-onset diabetes (especially in patients with pre-diabetes)

47
New cards

What mediates the uptake of statins for hepatic metabolism and biliary elimination?

Organic anion-transporting polypeptide |B| (OATP|B|)

48
New cards

What gene encodes for OATP|B|?

SLCO|B|

49
New cards

The allele of c.388G*5 and *15 with a haplotype of low-activity has what impact on statins?

decreased hepatic uptake = increased plasma exposure of statin = potential for increased myalgias (but no impact on effectiveness)

50
New cards

The allele of c.388G*IB with a haplotype of high-activity has what impact on statins?

increased hepatic uptake = decreased plasma exposure of statin = ??

51
New cards

If SLCO|B| variant is known and low functioning, what should be avoided?

avoid simvastatin or use lower doses

52
New cards

Brand name of ezetimibe

Zetia

53
New cards

Indication for ezetimibe

Hyperlipidemia, familial hypercholesterolemia

54
New cards

MOA for ezetimibe

Inhibits absorption of cholesterol at the brush border of the small intestine via
Niemann-Pick C1-Like1 (NPC1L1). This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood

55
New cards

CI for ezetimibe

Gallbladder disease, severe hepatic dysfunction

56
New cards

ADRs for ezetimibe

URTI, diarrhea, arthralgia, sinusitis, pain in extremities, +statin = myalgia, rhabdomyolysis, hepatotoxicity

57
New cards

key PKPD for ezetimibe

Enterohepatic circulation, half-life ~22 hours

58
New cards

DDI’s for ezetimibe

Plasma concentrations are significantly increased when administered with fibrates or cholestyramine

59
New cards

Ezetimibe impact on cholesterol:

decrease total cholesterol

with statin decreases LDL by ~25%

monotherapy: decrease LDL ~18%, decrease ApoB ~15%, decrease TG ~8-14%, increase HDL-cholesterol ~5%

60
New cards

Brand name of alirocumab

Praluent

61
New cards

Brand name of evolocumab

Repatha

62
New cards

Indication for alirocumab and evolocumab

hyperlipidemia, familial hypercholesterolemia,

63
New cards

MOA for alirocumab and evolocumab

human monoclonal antibody that binds to PCSK9 and increases the number of LDL receptors available to clear circulating LDL

64
New cards

CI for alirocumab and evolocumab

None

65
New cards

ADRs for alirocumab and evolocumab

nasopharyngitis, influenza, URTI, injection site reactions, back pain.

66
New cards

Key PKPD for alirocumab and evolocumab

subcutaneous injection every 2 or 4 weeks

67
New cards

DDIs for alirocumab and evolocumab

None identified

68
New cards

PCKS9-Inhibitors impact on cholesterol?

decrease total cholesterol, LDL ~50-70%, ApoB ~50%, TG~7-30%, Lp(a) ~25%, and increases HDL ~5-10%

69
New cards

Brand name of inclisiran

Leqvio

70
New cards

Indication for inclisiran

primary/secondary prevention of atherosclerotic cardiovascular disease, familial hypercholesterolemia

71
New cards

MOA of inclisiran

Small-interfering RNA (siRNA) LDL-C lowering therapy. Inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9) by blocking its synthesis, which is dependent on messenger RNA

72
New cards

CI for inclisiran

Pregnancy

73
New cards

ADRs for inclisiran

Injection site reactions, arthralgia

74
New cards

Pearls of inclisiran

subcutaneous injection into the abdomen, upper arm, or thigh once, then in 3 months, then every 6 months thereafter. Currently cannot be administered at home/pharmacy

75
New cards

Inclisiran impact on cholesterol

monotherapy: decrease LDL ~50%

76
New cards

Brand name of bempedoic acid

Nexletol

77
New cards

indication for bempedoic acid

primary/secondary prevention of atherosclerotic cardiovascular disease, familial hypercholesterolemia

78
New cards

MOA for bempedoic acid

Adenosine triphosphate-citrate lyase (ACL) inhibitor
ACL is an enzyme upstream in the cholesterol biosynthesis pathway
Bempedoic acid and its active metabolite require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1)
ACSVL1 is expressed primarily in the liver
Inhibition decreases cholesterol synthesis and lowers LDL-C in blood via upregulation of LDL receptors

79
New cards

CI for bempedoic acid

Pregnancy

80
New cards

ADRs for bempedoic acid

hyperuricemia (can cause gout flares with prior gout history), tendon rupture

81
New cards

Key PKPD for bempedoic acid

N/A

82
New cards

DDI for bempedoic acid

increases concentrations of pravastatin (max dose 40mg) and simvastatin (max dose 20mg)

83
New cards

Bempedoic acid impact on cholesterol

monotherapy: decreases LDL ~20-30%

with statin: additional 17% from statin lowering

84
New cards

Brand name of colesevelam

Welchol

85
New cards

Brand name of colestipol

Colestid

86
New cards

Brand name of cholestyramine

Prevalite, Questran

87
New cards

Indication for colesevelam

hyperlipidemia

88
New cards

MOA for colesevelam

Colesevelam binds with bile acids in the intestine to form an insoluble complex
that is eliminated in feces. This increased excretion of bile acids results in an increased oxidation of cholesterol to bile acid and a lowering of the serum cholesterol

89
New cards

CI for colesevelam

history of bowel obstruction, triglycerides > 500 mg/dL, hypertriglyceridemia induced pancreatitis

90
New cards

ADRs for colesevelam

constipation, dyspepsia, nausea, pancreatitis, bowel obstruction

91
New cards

Key PKPD for colesevelam

Drugs DO NOT ABSORB!! Excreted in feces

92
New cards

DDIs with colesevelam


Impacts drug absorption! Most medications need to be taken 1 hour before or

2 hours after the BAS to ensure adequate absorption:

  • Increases seizure activity or decreases phenytoin levels in patients taking phenytoin.

  • Decreases INR in patients taking warfarin

  • Increase TSH in patients taking thyroid hormone replacement therapy

93
New cards

Pearls of colesevelam

take with food:

packet/granules mix with 120-240ml of water, stir well and drink

tablets swallow with liquid

most need to be started at low dose and gradually increased

94
New cards

Bile acid sequestrants impact on cholesterol

Decrease LDL: colesevelam monotherapy 15%, colesevelam + statin 10-16%, colestipol monotherapy 16-27%, cholestyramine monotherapy 10.4%

Increase VLDL: may increase TGs

95
New cards

Brand name of omega-3-ethyl-esters?

Lovaza

96
New cards

Brand name of icosapent ethyl?

Vascepa

97
New cards

Indication for omega-3s

hyperlipidemia, hypertriglyceridemia

98
New cards

MOA of omega-3s

Reduction in the hepatic production of triglyceride-rich very low-density
lipoproteins. Possible cellular mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic mitochondrial and peroxisomal beta-oxidation, and a reduction in the hepatic synthesis of triglycerides

99
New cards

CI for omega-3s

Hypersensitivity to drug, fish, or shellfish (use with caution)

100
New cards

ADRs for omega-3s

diarrhea, fishy breath, burping, change in taste, elevated LFTs